MedTrace Logo

Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis

NCT01188655 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 89

Last updated 2011-09-12

Study results available
· View outcomes & findings →

Summary

This observational study will be a documentation of the prescribing and administration practices of Enbrel® and their impact on ankylosing spondylitis patients outcome in a real life setting.

Conditions

  • Spondylitis, Ankylosing

Interventions

DRUG

Enbrel

The patients will be treated in accordance with the requirements of the labeling of Enbrel® in Austria. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment. To record complete dosing information, initial dose will be documented at baseline and any change will be documented with date, dose and reason at the subsequent visits.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2010-03-31
Completion
2010-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01188655 on ClinicalTrials.gov